Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy
- 30 December 2011
- journal article
- research article
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 18 (1), 69-73
- https://doi.org/10.1007/s13365-011-0068-8
Abstract
HIV-associated neurocognitive disorders (HAND) persist despite plasma HIV RNA suppression with antiretrovirals (ARV). Sequestered reservoirs in the central nervous system and circulating monocytes are theorized to contribute to persistent brain injury. We previously demonstrated that elevated intracellular HIV DNA from circulating cells was associated with HAND in ARV-treated and ARV-naive subjects. We now report that failure to suppress intra-monocyte HIV DNA 3.5 years after initiating ARV is linked to persistent HAND and subjects with dementia are least likely to suppress intra-monocyte HIV DNA at 3.5 years. These findings suggest that antiviral strategies may need to target intra-monocyte HIV DNA.This publication has 15 references indexed in Scilit:
- Cognitive Performance Related to HIV-1-Infected MonocytesThe Journal of Neuropsychiatry and Clinical Neurosciences, 2012
- Hide and Seek… Can We Eradicate HIV by Treatment Intensification?The Journal of Infectious Diseases, 2011
- Increased Monocyte Turnover from Bone Marrow Correlates with Severity of SIV Encephalitis and CD163 Levels in PlasmaPLoS Pathogens, 2010
- Characteristics of Activated Monocyte Phenotype Support R5-Tropic Human Immunodeficiency VirusImmunology and Immunogenetics Insights, 2009
- HIV-associated neurocognitive disease continues in the antiretroviral era.2008
- The CD16+ Monocyte Subset Is More Permissive to Infection and Preferentially Harbors HIV-1 In VivoThe Journal of Immunology, 2007
- Circulating proviral HIV DNA and HIV-associated dementiaAIDS, 2005
- The neuropathogenesis of AIDSNature Reviews Immunology, 2005
- Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.2004
- The neurological features of acute HIV infection.1988